

Michail Vikelis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3695942/publications.pdf>

Version: 2024-02-01

12
papers

240
citations

1162889

8
h-index

1199470

12
g-index

13
all docs

13
docs citations

13
times ranked

239
citing authors

#	ARTICLE	IF	CITATIONS
1	Patients'™ preferences for headache acute and preventive treatment. <i>Journal of Headache and Pain</i> , 2017, 18, 102.	2.5	45
2	Clinical experience with transcutaneous supraorbital nerve stimulation in patients with refractory migraine or with migraine and intolerance to topiramate: a prospective exploratory clinical study. <i>BMC Neurology</i> , 2017, 17, 97.	0.8	42
3	Endogenous Melatonin Levels and Therapeutic Use of Exogenous Melatonin in Migraine: Systematic Review and Meta-Analysis. <i>Headache</i> , 2020, 60, 1273-1299.	1.8	42
4	Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment. <i>Journal of Headache and Pain</i> , 2018, 19, 87.	2.5	28
5	Onabotulinumtoxin-A treatment in Greek patients with chronic migraine. <i>Journal of Headache and Pain</i> , 2016, 17, 84.	2.5	27
6	A new era in headache treatment. <i>Neurological Sciences</i> , 2018, 39, 47-58.	0.9	13
7	Beyond chronic migraine: a systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 923-944.	1.4	12
8	Long-term adherence, safety, and efficacy of repeated onabotulinumtoxinA over five years in chronic migraine prophylaxis. <i>Acta Neurologica Scandinavica</i> , 2022, 145, 676-683.	1.0	12
9	Open Label Prospective Experience of Supplementation with a Fixed Combination of Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis. <i>Journal of Clinical Medicine</i> , 2021, 10, 67.	1.0	7
10	A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine. <i>Expert Review of Neurotherapeutics</i> , 2022, 22, 469-488.	1.4	6
11	Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis. <i>Toxins</i> , 2022, 14, 296.	1.5	3
12	Prospective Comparison of Longer Needle Lengths to Assess the Risk of OnabotulinumtoxinA-Associated Neck Pain in Patients with Chronic Migraine. <i>Toxins</i> , 2022, 14, 434.	1.5	3